Cargando…

S171: HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET

Detalles Bibliográficos
Autores principales:	Wang, Yu-Hung, Lin, Chien-Chin, Yao, Chi-Yuan, Gurashi, Kristian, Amaral, Fabio M. R., Nicosia, Luciano, Wingelhofer, Bettina, Batta, Kiran, Wiseman, Daniel, Hou, Hsin-An, Chou, Wen Chien, Tien, Hwei-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428417/ http://dx.doi.org/10.1097/01.HS9.0000967596.07975.9f

Ejemplares similares

P720: A BONE MARROW MICROENVIRONMENTAL CELL SIGNATURE SCORING SYSTEM INDEPENDENTLY PREDICTED SURVIVAL AND DRUG RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS
por: Wang, Yu-Hung, et al.
Publicado: (2023)

P691: MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS
por: Wang, Yu-Hung, et al.
Publicado: (2023)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA
por: Wang, Yu-Hung, et al.
Publicado: (2023)

Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome
por: Wiseman, Daniel H, et al.
Publicado: (2020)

Is MDMX the better target?
por: Kon, Ning, et al.
Publicado: (2018)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

T171. HIGH POLYGENIC BURDEN IS ASSOCIATED WITH BLOOD DNA METHYLATION CHANGES IN INDIVIDUALS WITH SUICIDAL BEHAVIOR
por: Cabrera, Brenda, et al.
Publicado: (2020)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome
por: Yang, Yi-Tsung, et al.
Publicado: (2018)

S171. EFFECT OF DAOA GENETIC VARIATION ON WHITE MATTER ALTERATION IN CORPUS CALLOSUM IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA
por: Su, Wenjun, et al.
Publicado: (2020)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

High BM plasma S100A8/A9 is associated with a perturbed microenvironmentand poor prognosis in myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2023)

MDMX elevation by a novel Mdmx–p53 interaction inhibitor mitigates neuronal damage after ischemic stroke
por: Yan, Haomin, et al.
Publicado: (2022)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Functions of MDMX in the Modulation of the p53-Response
por: Lenos, Kristiaan, et al.
Publicado: (2011)

MDM4 (MDMX) and its Transcript Variants
por: Mancini, F, et al.
Publicado: (2009)

Role of Mdm2 and Mdmx in DNA repair
por: Eischen, Christine M.
Publicado: (2017)

S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES
por: Dussiau, Charles, et al.
Publicado: (2023)

A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm
por: Dong, Athena, et al.
Publicado: (2022)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

M171. THE GENE-SHARING RELATIONSHIP OF SCHIZOPHRENIA WITH OTHER MENTAL OR SYSTEMIC DISORDERS: A DISEASE-SIMILARITY NETWORK ANALYSIS FOCUSED ON EGOCENTRIC NETWORK
por: Hoon Jeong, Seong, et al.
Publicado: (2020)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

FOR BETTER AND WORSE? THE IMPORTANCE OF CLOSENESS AND AGE FOR SPOUSES’ CARDIOMETABOLIC SIMILARITY
por: Wilson, Stephanie J, et al.
Publicado: (2019)

Controlling the Mdm2-Mdmx-p53 Circuit
por: Waning, David L., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j1en80qh99iels6idnrv7lb1lf